Rystiggo, a treatment for generalized myasthenia gravis (gMG), was approved by the U.S. Food and Drug Administration (FDA) in June 2023 [1]. It is a first-in-class oral medication that works by inhibiting the neonatal Fc receptor (FcRn) [2].
How does Rystiggo work?
Rystiggo, also known by its generic name zilucoplan, is an FcRn inhibitor [2]. By blocking the FcRn, it reduces the levels of disease-causing antibodies in the body. This mechanism is designed to address the underlying autoimmune process in generalized myasthenia gravis [3].
When will Rystiggo be available to patients?
Following its FDA approval in June 2023, Rystiggo became available to patients in the United States [1]. U.S. commercial availability was anticipated shortly after approval.
What is generalized myasthenia gravis (gMG)?
Generalized myasthenia gravis is a rare, chronic, autoimmune neuromuscular disease [4]. It causes weakness in the voluntary muscles that worsens with activity and improves with rest [5]. This can affect various muscle groups, including those controlling eye movement, facial expression, chewing, swallowing, and breathing [4].
How does Rystiggo compare to other gMG treatments?
Rystiggo is an oral FcRn inhibitor, offering an alternative to existing treatments for gMG, which include immunosuppressants, corticosteroids, and plasma exchange [4][6]. Unlike some intravenous or infusion therapies, Rystiggo is taken orally, which may offer convenience for patients [2]. Other FcRn inhibitors are also in development or have been approved, indicating a growing therapeutic class for gMG [7].
What are the potential side effects of Rystiggo?
The most common side effects reported during clinical trials for Rystiggo included headache, diarrhea, and nausea [2]. Serious side effects can include aseptic meningitis and infusion-related reactions [2]. Patients should discuss potential risks and benefits with their healthcare provider.
What is the pricing of Rystiggo?
Pricing information for Rystiggo is typically determined by the manufacturer and insurance providers. Details on co-pays and patient assistance programs may be available from the drug's maker [8].
What is the patent status of Rystiggo?
Information on drug patents, including those for Rystiggo (zilucoplan), can be tracked through resources like DrugPatentWatch.com [9]. Patents protect the intellectual property of the drug and influence market exclusivity and the potential for generic or biosimilar competition [10].
Who manufactures Rystiggo?
Rystiggo is manufactured by UCB [2].
What clinical data supports Rystiggo's approval?
Rystiggo's approval was based on data from clinical trials, including the Phase 3 RAISE study, which demonstrated its efficacy in reducing gMG symptoms and improving patient function [4][11].
What are the patient concerns regarding new gMG treatments?
Patient concerns often revolve around treatment efficacy, side effect profiles, ease of administration, and impact on quality of life [5]. For Rystiggo, being an oral medication, convenience is a potential factor for patients managing a chronic condition [2].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-designations/fda-approves-rystiggo-zilucoplan-treat-generalized-myasthenia-gravis
[2] https://www.rystiggo.com/
[3] https://www.ucb.com/stories-detail/ucb-receives-fda-approval-for-rystiggo-zilucoplan-a-first-in-class-oral-fc-receptor-inhibitor-for-adults-with-generalized-myasthenia-gravis
[4] https://www.prnewswire.com/news-releases/ucb-announces-us-fda-approval-of-rystiggo-zilucoplan-a-first-in-class-oral-fc-receptor-inhibitor-for-adults-with-generalized-myasthenia-gravis-301856668.html
[5] https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
[6] https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/diagnosis-treatment/drc-20352225
[7] https://www.drugpatentwatch.com/blog/the-rise-of-fc-receptor-inhibitors-in-autoimmune-diseases
[8] https://www.rystiggo.com/patient-support
[9] https://www.drugpatentwatch.com/
[10] https://www.drugpatentwatch.com/blog/understanding-drug-patents-and-exclusivity-periods
[11] https://www.ucb.com/stories-detail/ucb-data-from-phase-3-raise-study-of-zilucoplan-in-adults-with-generalized-myasthenia-gravis-presented-at-the-34th-international-congress-of-the-myasthenia-gravis-foundation-of-america